Portal de Periódicos da CAPES

Long term safety and efficacy of donepezil in the treatment of dementia in Alzheimer's disease in adults with Down syndrome: open label study

2003; Wiley; Volume: 18; Issue: 6 Linguagem: Inglês

10.1002/gps.859

1099-1166

V. P. Prasher, Claire Adams, R Holder,

Chronic Disease Management Strategies

International Journal of Geriatric PsychiatryVolume 18, Issue 6 p. 549-551 Research Letter Long term safety and efficacy of donepezil in the treatment of dementia in Alzheimer's disease in adults with Down syndrome: open label study V. P. Prasher, Corresponding Author V. P. Prasher [email protected] Monyhull Hospital, Birmingham, UKMonyhull Hospital, Monyhull Hall Road, Kings Norton, Birmingham, B30 3QB, UK.Search for more papers by this authorC. Adams, C. Adams Monyhull Hospital, Birmingham, UKSearch for more papers by this authorR. Holder, R. Holder Department of Statistics, University of Birmingham, Birmingham, UKSearch for more papers by this authorThe Down Syndrome Research Group, The Down Syndrome Research Group The Down Syndrome Group are: Dr Ashok Roy and Dr G. Cassidy, Brooklands; Dr Meera Roy, Monyhull Hospital, Dr T. Mlele, Heath Lane Hospital; Dr K. Trezise and Dr E. Napier, Ridge Hill Hospital; Dr J. Langton, Telford Community Support Team, Shropshire; Dr D. Perry and Dr G. Marston, Gulson Hospital; Dr D. Sansom, Royal Leamington Spa Rehabilatation Hospital.Search for more papers by this author V. P. Prasher, Corresponding Author V. P. Prasher [email protected] Monyhull Hospital, Birmingham, UKMonyhull Hospital, Monyhull Hall Road, Kings Norton, Birmingham, B30 3QB, UK.Search for more papers by this authorC. Adams, C. Adams Monyhull Hospital, Birmingham, UKSearch for more papers by this authorR. Holder, R. Holder Department of Statistics, University of Birmingham, Birmingham, UKSearch for more papers by this authorThe Down Syndrome Research Group, The Down Syndrome Research Group The Down Syndrome Group are: Dr Ashok Roy and Dr G. Cassidy, Brooklands; Dr Meera Roy, Monyhull Hospital, Dr T. Mlele, Heath Lane Hospital; Dr K. Trezise and Dr E. Napier, Ridge Hill Hospital; Dr J. Langton, Telford Community Support Team, Shropshire; Dr D. Perry and Dr G. Marston, Gulson Hospital; Dr D. Sansom, Royal Leamington Spa Rehabilatation Hospital.Search for more papers by this author First published: 28 May 2003 https://doi.org/10.1002/gps.859Citations: 45 AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES National Institute for Clinical Excellence. 2001. Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease. London. Prasher VP, Huxley A, Haque MS and the Down syndrome dementia Group. 2002. A 24-week, double-blind, placebo- controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease-Pilot study. Int J Geriatr Psychiatry 17: 270–278. World Health Organisation. 1993. The ICD-10 Classification of Mental and Behavioural Disorders. Diagnostic Criteria for Research. WHO: Geneva. Citing Literature Volume18, Issue6June 2003Pages 549-551 ReferencesRelatedInformation